<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364090">
  <stage>Registered</stage>
  <submitdate>21/04/2013</submitdate>
  <approvaldate>30/04/2013</approvaldate>
  <actrnumber>ACTRN12613000479707</actrnumber>
  <trial_identification>
    <studytitle>	Randomized Control Trial between Two Hourly Oral Misoprostol  and Propess for Induction of Labor</studytitle>
    <scientifictitle>	Randomized Control Trial between Two Hourly Oral Misoprostol  and Propess for Induction of Labor</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Induction of labor.</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group A: 20 mcg misoprostol orally every 2 hours
A tablet (200 mcg) misoprostol will be dissolved in 200 mL water, producing a 1 mcg/mL solution. Achieving a uniform solution may be facilitated by crushing the tablet and/or using warm water to dissolve. Each 2 hourly oral dose will be provided as 20 mL of the misoprostol solution. Dosing will be continued until the subject achieves active labor (regular contractions occurring each 3 to 5 minutes, and lasting at least 60 seconds).
</interventions>
    <comparator>Group B: Propess 'Registered Trademark'  vaginal dinoprostone pessary
A 10 mg dinoprostone pessary will be inserted vaginally until the subject achieves active labor (regular contractions occurring each 3 to 5 minutes, and lasting at least 60 seconds). It will be removed after 24 hours if active labor does not occur. 
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is proportion of subjects achieving vaginal delivery within 24 hours. </outcome>
      <timepoint>Vaginal delivery within 24 hours. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean time to delivery


</outcome>
      <timepoint>At delivery, the mean time from start of labor till delivery will be compared between the two groups.

</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of cesarean section</outcome>
      <timepoint>The rate of cesarean section in the two groups from the start of induction will be compared.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of oxytocin augmentation.  
</outcome>
      <timepoint>The duration of oxytocin use from start till delivery will be determined.

</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apgar score &lt;7 at 5 minutes</outcome>
      <timepoint>Apgar score at 5 minutes will be determined.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neonatal Intensive Care Unit (NICU) admission.</outcome>
      <timepoint>After delivery, the rate of NICU admission will be compared in the two groups. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Singleton pregnancy for induction of labor
2.	No contraindication to either drug
3.	Bishop score &lt;6
4.	Documented nonreactive stress test (NST)
5.	Written informed consent
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	&lt;34 weeks gestation
2.	Severe pregnancy induced hypertension 
3.	Previous C/S or other uterine surgery
4.	Parity 4 and more
5.	Current uterine contractions
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Women who meet eligibility criteria will be approached for possible enrollment. Allocation to the treatment arms will be done by opening a sealed opaque envelop. </concealment>
    <sequence>Randomization will be achieved via a computer-generated list using 3 block sizes. The resultant 37 blocks will be randomized to determine final treatment order. The study will not be blinded, increasing the importance of diligent attention to allocation concealment. For this purpose, sealed opaque envelopes containing sequential treatment order assignments will be provided to the recruitment center (define where that is). In the event multiple subjects are available at the same time, sequential opening of envelopes will assure “picking” the treatments is precluded. The screening and enrollment logs will be maintained at the recruitment center.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>None</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>19/11/2012</anticipatedstartdate>
    <actualstartdate>19/11/2012</actualstartdate>
    <anticipatedenddate>30/12/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>King Fahad Armed Forces Hospital</primarysponsorname>
    <primarysponsoraddress>PO Box 80215,
Jeddah, 21589
Saudi Arabia</primarysponsoraddress>
    <primarysponsorcountry>Saudi Arabia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>None.</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The research hypothesis is that more women for whom induction of labor is indicated will undergo vaginal delivery within 24 hours with 2 hourly treatment with 20 mcg oral misoprostol compared with 10 mg dinoprostone delivered via vaginal pessary.The primary objective is to compare the achievement of vaginal delivery within 24 hoursfollowing induction with static dose oral misoprostol and sustained-release vaginal dinoprostone.   </summary>
    <trialwebsite>None.</trialwebsite>
    <publication>None.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>None.</publicnotes>
    <ethicscommitee>
      <ethicname>King Fahad Armed Forces Hospital</ethicname>
      <ethicaddress>PO Box 80215, Jeddah 21589</ethicaddress>
      <ethicapprovaldate>1/11/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/10/2012</ethicsubmitdate>
      <ethiccountry>Saudi Arabia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Abdulrahim Rouzi</name>
      <address>King Abdulaziz University
PO Box 80215, Jeddah 21589</address>
      <phone>+966 505602587</phone>
      <fax />
      <email>aarouzi@gmail.com</email>
      <country>Saudi Arabia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Abdulrahim Rouzi</name>
      <address>King Abdulaziz University
PO Box 80215
Jeddah 21589</address>
      <phone>+966 505602587</phone>
      <fax />
      <email>aarouzi@gmail.com</email>
      <country>Saudi Arabia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Abdulrahim Rouzi</name>
      <address>King Abdulaziz University
PO Box 80215
Jeddah 21589</address>
      <phone>+966 505602587</phone>
      <fax />
      <email>aarouzi@gmail.com</email>
      <country>Saudi Arabia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Abdulrahim Rouzi</name>
      <address>PO Box 80215</address>
      <phone>966505602587</phone>
      <fax />
      <email>aarouzi@gmail.com</email>
      <country>Saudi Arabia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>